2D phase contrast blood flow velocity measurements of the thoracic vasculature

comparison of the effect of gadofosveset trisodium and gadopentetate dimeglumine

Marcus R. Makowski, Andrea J. Wiethoff, Hans U. Ebersberger, René M. Botnar, Reza Razavi, Tobias Schaeffter, Gerald F. Greil

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aim of this prospective study is to compare the performance of 2D time-resolved phase-contrast (PC) MRI prior to and after the administration of an intravascular (gadofosveset-trisodium) and extravascular (gadopentetate-dimeglumine) contrast agent in the same patient in the cardiovascular system. This study was approved by the ethics committee (Study-Number-07/Q0704/2) and registered with the MedicinesAndHealthcareProductsRegulatoryAgency (MHRA-Study-Number-28482/0002/001-0001, EudraCT-Number-2006-007042). All patients signed an informed consent. 20 patients were examined using a 1.5T MR-scanner and 32-channel-coil-technology. Gadopentetate-dimeglumine (GdD) and gadofosveset-trisodium (GdT) were administered in the same patient on consecutive days. Image quality, velocity-to-noise-ratios (VNRs) and standard-deviation of blood-flow-velocities (phase-noise) were compared between GdT, GdD and non-contrast-enhanced imaging. On both days pre- and post-contrast-scans were performed. The administration of GdT significantly improved the delineation of the perfused lumen and the VNR compared to GdD and non-contrast-enhanced imaging. Standard deviations of through-plane and in-plane velocity-measurements (phase-noise) were significantly reduced after GdT administration (p < 0.05). No significant differences (p > 0.05) were measured regarding absolute flow values prior to and after the administration of GdD and GdT. PC flow imaging benefits from the administration of an intravascular contrast agent by improving the delineation of the perfused lumen and reducing phase noise in flow measurements.

Original languageEnglish (US)
Pages (from-to)409-416
Number of pages8
JournalInternational Journal of Cardiovascular Imaging
Volume31
Issue number2
DOIs
StatePublished - Feb 27 2015

Fingerprint

Gadolinium DTPA
Blood Flow Velocity
Thorax
Noise
Contrast Media
Ethics Committees
Cardiovascular System
Informed Consent
gadofosveset trisodium
Prospective Studies
Technology

Keywords

  • Aorta
  • Contrast media
  • Magnetic resonance imaging
  • Pulsatile flow

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

2D phase contrast blood flow velocity measurements of the thoracic vasculature : comparison of the effect of gadofosveset trisodium and gadopentetate dimeglumine. / Makowski, Marcus R.; Wiethoff, Andrea J.; Ebersberger, Hans U.; Botnar, René M.; Razavi, Reza; Schaeffter, Tobias; Greil, Gerald F.

In: International Journal of Cardiovascular Imaging, Vol. 31, No. 2, 27.02.2015, p. 409-416.

Research output: Contribution to journalArticle

Makowski, Marcus R. ; Wiethoff, Andrea J. ; Ebersberger, Hans U. ; Botnar, René M. ; Razavi, Reza ; Schaeffter, Tobias ; Greil, Gerald F. / 2D phase contrast blood flow velocity measurements of the thoracic vasculature : comparison of the effect of gadofosveset trisodium and gadopentetate dimeglumine. In: International Journal of Cardiovascular Imaging. 2015 ; Vol. 31, No. 2. pp. 409-416.
@article{14964125c991411b9ca18e3e55047f3a,
title = "2D phase contrast blood flow velocity measurements of the thoracic vasculature: comparison of the effect of gadofosveset trisodium and gadopentetate dimeglumine",
abstract = "The aim of this prospective study is to compare the performance of 2D time-resolved phase-contrast (PC) MRI prior to and after the administration of an intravascular (gadofosveset-trisodium) and extravascular (gadopentetate-dimeglumine) contrast agent in the same patient in the cardiovascular system. This study was approved by the ethics committee (Study-Number-07/Q0704/2) and registered with the MedicinesAndHealthcareProductsRegulatoryAgency (MHRA-Study-Number-28482/0002/001-0001, EudraCT-Number-2006-007042). All patients signed an informed consent. 20 patients were examined using a 1.5T MR-scanner and 32-channel-coil-technology. Gadopentetate-dimeglumine (GdD) and gadofosveset-trisodium (GdT) were administered in the same patient on consecutive days. Image quality, velocity-to-noise-ratios (VNRs) and standard-deviation of blood-flow-velocities (phase-noise) were compared between GdT, GdD and non-contrast-enhanced imaging. On both days pre- and post-contrast-scans were performed. The administration of GdT significantly improved the delineation of the perfused lumen and the VNR compared to GdD and non-contrast-enhanced imaging. Standard deviations of through-plane and in-plane velocity-measurements (phase-noise) were significantly reduced after GdT administration (p < 0.05). No significant differences (p > 0.05) were measured regarding absolute flow values prior to and after the administration of GdD and GdT. PC flow imaging benefits from the administration of an intravascular contrast agent by improving the delineation of the perfused lumen and reducing phase noise in flow measurements.",
keywords = "Aorta, Contrast media, Magnetic resonance imaging, Pulsatile flow",
author = "Makowski, {Marcus R.} and Wiethoff, {Andrea J.} and Ebersberger, {Hans U.} and Botnar, {Ren{\'e} M.} and Reza Razavi and Tobias Schaeffter and Greil, {Gerald F.}",
year = "2015",
month = "2",
day = "27",
doi = "10.1007/s10554-014-0565-y",
language = "English (US)",
volume = "31",
pages = "409--416",
journal = "International Journal of Cardiovascular Imaging",
issn = "1569-5794",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - 2D phase contrast blood flow velocity measurements of the thoracic vasculature

T2 - comparison of the effect of gadofosveset trisodium and gadopentetate dimeglumine

AU - Makowski, Marcus R.

AU - Wiethoff, Andrea J.

AU - Ebersberger, Hans U.

AU - Botnar, René M.

AU - Razavi, Reza

AU - Schaeffter, Tobias

AU - Greil, Gerald F.

PY - 2015/2/27

Y1 - 2015/2/27

N2 - The aim of this prospective study is to compare the performance of 2D time-resolved phase-contrast (PC) MRI prior to and after the administration of an intravascular (gadofosveset-trisodium) and extravascular (gadopentetate-dimeglumine) contrast agent in the same patient in the cardiovascular system. This study was approved by the ethics committee (Study-Number-07/Q0704/2) and registered with the MedicinesAndHealthcareProductsRegulatoryAgency (MHRA-Study-Number-28482/0002/001-0001, EudraCT-Number-2006-007042). All patients signed an informed consent. 20 patients were examined using a 1.5T MR-scanner and 32-channel-coil-technology. Gadopentetate-dimeglumine (GdD) and gadofosveset-trisodium (GdT) were administered in the same patient on consecutive days. Image quality, velocity-to-noise-ratios (VNRs) and standard-deviation of blood-flow-velocities (phase-noise) were compared between GdT, GdD and non-contrast-enhanced imaging. On both days pre- and post-contrast-scans were performed. The administration of GdT significantly improved the delineation of the perfused lumen and the VNR compared to GdD and non-contrast-enhanced imaging. Standard deviations of through-plane and in-plane velocity-measurements (phase-noise) were significantly reduced after GdT administration (p < 0.05). No significant differences (p > 0.05) were measured regarding absolute flow values prior to and after the administration of GdD and GdT. PC flow imaging benefits from the administration of an intravascular contrast agent by improving the delineation of the perfused lumen and reducing phase noise in flow measurements.

AB - The aim of this prospective study is to compare the performance of 2D time-resolved phase-contrast (PC) MRI prior to and after the administration of an intravascular (gadofosveset-trisodium) and extravascular (gadopentetate-dimeglumine) contrast agent in the same patient in the cardiovascular system. This study was approved by the ethics committee (Study-Number-07/Q0704/2) and registered with the MedicinesAndHealthcareProductsRegulatoryAgency (MHRA-Study-Number-28482/0002/001-0001, EudraCT-Number-2006-007042). All patients signed an informed consent. 20 patients were examined using a 1.5T MR-scanner and 32-channel-coil-technology. Gadopentetate-dimeglumine (GdD) and gadofosveset-trisodium (GdT) were administered in the same patient on consecutive days. Image quality, velocity-to-noise-ratios (VNRs) and standard-deviation of blood-flow-velocities (phase-noise) were compared between GdT, GdD and non-contrast-enhanced imaging. On both days pre- and post-contrast-scans were performed. The administration of GdT significantly improved the delineation of the perfused lumen and the VNR compared to GdD and non-contrast-enhanced imaging. Standard deviations of through-plane and in-plane velocity-measurements (phase-noise) were significantly reduced after GdT administration (p < 0.05). No significant differences (p > 0.05) were measured regarding absolute flow values prior to and after the administration of GdD and GdT. PC flow imaging benefits from the administration of an intravascular contrast agent by improving the delineation of the perfused lumen and reducing phase noise in flow measurements.

KW - Aorta

KW - Contrast media

KW - Magnetic resonance imaging

KW - Pulsatile flow

UR - http://www.scopus.com/inward/record.url?scp=84925503344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925503344&partnerID=8YFLogxK

U2 - 10.1007/s10554-014-0565-y

DO - 10.1007/s10554-014-0565-y

M3 - Article

VL - 31

SP - 409

EP - 416

JO - International Journal of Cardiovascular Imaging

JF - International Journal of Cardiovascular Imaging

SN - 1569-5794

IS - 2

ER -